Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi will see the number of shots per patient fall. But that doesn't mean they'll necessarily take a sales hit, with the move potentially expanding overall access and providing a bump both drugmakers could use.
If the U.K. adopts the two-shot model, it may use the cash it saves to vaccinate boys against HPV.
The success of Australia's HPV vaccination catch-up program has given the country a world-leading trove of real-world data on the effectiveness of Merck's Gardasil. By mining this database, researchers have estimated the vaccine halves the risk of young women developing high-grade cervical abnormalities.
The FDA accepted Merck's application for V503, a next-generation HPV vaccine designed to usurp Gardasil, setting the stage for a near-term approval and some likely blockbusting sales figures.
The reasons for low uptake of HPV vaccines have been well researched and widely discussed by academia and government agencies, yet this knowledge has done nothing to increase adoption. Now, the President's Cancer Panel has weighed in to give momentum to a public health campaign it views as a "profound opportunity" to prevent cancer.
The President's Cancer Panel is urging federal and state health authorities to do a better job protecting children from preventable cancers by improving access to the HPV vaccine, which could mean a big bump in sales.
When the Centers for Disease Control and Prevention looked into the reasons behind low uptake of GlaxoSmithKline's and Merck's human papillomavirus vaccines last year, the effect of parental attitudes to sex grabbed the headlines. Yet while parents may fear the vaccine will lead to risky sex, all the evidence suggests otherwise.
A new study in JAMA Pediatrics finds that sex and money each play a role in U.S. parents' reluctance to vaccinate their children against the human papillomavirus. But a lack of easy-to-understand information about the shots--and often, the lack of a doctor's clear recommendation for them--are also helping to depress vaccination rates.
A competitor is threatening to chip away at sales of Merck's human papillomavirus vaccine Gardasil. Fortunately for Merck, it is the company developing the rival.
The layoffs and cuts outlined by Merck earlier this month showed the faith it has in the vaccine unit to drive growth over the coming years. And this week brought fresh data to back its decision, with third-quarter results showing strong demand for vaccines propping up other struggling areas of the firm.